Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data

Diabetes, Obesity and Metabolism

Volumn 19, Issue 3, 2017, Pages 329-335

  Bain, Steve ^a   Druyts, Eric ^b,c   Balijepalli, Chakrapani ^b,d   Baxter, Carl A ^e   Currie, Craig J ^f,g   Das, Romita ^e   Donnelly, Richard ^h   Khunti, Kamlesh ⁱ   Langerman, Haya ^e   Leigh, Paul ^e   Siliman, Gaye ^b   Thorlund, Kristian ^b,j   Toor, Kabirraaj ^b   Vora, Jiten ^k   Mills, Edward J ^b,j  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b PRECISION HEALTH ECONOMICS   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d SIMON FRASER UNIVERSITY   (Canada)

^e MSD Development Laboratories   (United Kingdom)

^f Global Epidemiology   (United Kingdom)

^g CARDIFF UNIVERSITY   (United Kingdom)

^h UNIVERSITY OF NOTTINGHAM   (United Kingdom)

ⁱ UNIVERSITY OF LEICESTER   (United Kingdom)

^j MCMASTER UNIVERSITY   (Canada)

^k ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

more..

Author keywords

cardiovascular disease; meta analysis; sulphonylureas; systematic review; T2DM

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; SODIUM GLUCOSE COTRANSPORTER 2;

ARTICLE; BAYES THEOREM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; DISEASE ASSOCIATION; HEART INFARCTION; HUMAN; META ANALYSIS; MONOTHERAPY; MORTALITY RISK; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; AGONISTS; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETES MELLITUS, TYPE 2; MORTALITY; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODEL; STROKE; SURVIVAL RATE;

BAYES THEOREM; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MORTALITY; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; SODIUM-GLUCOSE TRANSPORTER 2; STROKE; SULFONYLUREA COMPOUNDS; SURVIVAL RATE; THIAZOLIDINEDIONES;

EID: 85007353029     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12821     Document Type: Article

References (30)

1. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. Br Med J. 2006;332:73-78.
2. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44(suppl 2):S14-21.
3. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471.
4. Abdelmoneim AS, Eurich DT, Light PE, et al. Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. Diabetes Obes Metab. 2015;17:523-532.
5. Samaha FF, Heineman FW, Ince C, Fleming J, Balaban RS. ATP-sensitive potassium channel is essential to maintain basal coronary vascular tone in vivo. Am J Physiol. 1992;262:C1220-1227.
6. Schulz R, Rose J, Heusch G. Involvement of activation of ATP-dependent potassium channels in ischemic preconditioning in swine. Am J Physiol. 1994;v267:vH1341-1352.
7. Cleveland JC Jr, Meldrum DR, Cain BS, Banerjee A, Harken AH. Oral sulphonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation. 1997;96:29-32.
8. Scognamiglio R, Avogaro A, Vigili de Kreutzenberg S, et al. Effects of treatment with sulphonylurea drugs or insulin on ischemia-induced myocardial dysfunction in T2DM. Diabetes. 2002;51:808-812.
9. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007;30:389-394.
10. Mellbin LG, Ryden L, Riddle MC, et al. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J. 2013;34:3137-3144.
11. Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev. 2008;24:353-363.
12. Hemmingsen B, Schroll JB, Lund SS, et al. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD009008.
13. Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15:938-953.
14. Rosenstock J, Marx N, Kahn SE, et al. Cardiovascular outcome trials in T2DM and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res. 2013;10:289-301.
15. Forst T, Hanefeld M, Jacob S, et al. Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Diab Vasc Dis Res. 2013;10:302-314.
16. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008;168:2070-2080.
17. Monami M, Vitale V, Ambrosio ML, et al. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials. Adv Ther. 2012;29:736-746.
18. Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care. 2008;31:1672-1678.
19. Rados DV, Pinto LC, Remonti LR. Sulfonylureas are not associated with increased mortality: meta-analysis and trial sequential analysis of randomized clinical trials. American Diabetes Association 2015 Scientific Sessions; June 5 – 9, 2015; Boston, MA.
20. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Br Med J (Clin Res Ed). 2011;343:d5928.
21. Dias S, Welton NJ, Sutton AJ, Ades AE. A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials [Internet]. London, England: National Institute for Health and Care Excellence (NICE); 2014 April.
22. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170:1191-1201.
23. Stone JC, Furuya-Kanamori L, Barendregt JJ, Doi SA. Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes? Pharmacoepidemiol Drug Saf. 2015;24:223-227.
24. Belcher G, Lambert C, Goh KL, Edwards G, Valbuena M. Cardiovascular effects of treatment of T2DM with pioglitazone, metformin and gliclazide. Int J Clin Pract. 2004;58:833-837.
25. Phung OJ, Schwartzman E, Allen RW, Engel SS, Rajpathak SN. Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med. 2013;30:1160-1171.
26. Simpson SH, Lee J, Choi S, Vandermeer B, Abdelmoneim AS, Featherstone TR. Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol. 2015;3:43-51.
27. Marx N, Rosenstock J, Kahn SE, et al. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in T2DM (CAROLINA(R)). Diab Vasc Dis Res. 2015;12:164-174.
28. Vaccaro O, Masulli M, Bonora E, et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in T2DM. Diabetes Care. 2012;35:e82.
29. UKPDS 33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with T2DM (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. [Erratum appears in Lancet 1999 Aug 14;354(9178):602]. Lancet. 1998;352:837-853.
30. Heller SR. A summary of the ADVANCE Trial. Diabetes Care. 2009;32(suppl 2):S357-361.